Literature DB >> 15844625

Technology evaluation: Rexin-G, Epeius Biotechnologies.

Michael Morse1.   

Abstract

Rexin-G is a 'pathotropic', tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene, under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. The therapy is currently undergoing phase I/II clinical trials.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15844625

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  5 in total

Review 1.  Targeted imaging and therapy of brain cancer using theranostic nanoparticles.

Authors:  Mahaveer Swaroop Bhojani; Marcian Van Dort; Alnawaz Rehemtulla; Brian D Ross
Journal:  Mol Pharm       Date:  2010-10-27       Impact factor: 4.939

2.  Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer.

Authors:  Evanthia Galanis; Stephanie K Carlson; Nathan R Foster; Val Lowe; Fernando Quevedo; Robert R McWilliams; Axel Grothey; Aminah Jatoi; Steven R Alberts; Joseph Rubin
Journal:  Mol Ther       Date:  2008-03-18       Impact factor: 11.454

Review 3.  The big picture on nanomedicine: the state of investigational and approved nanomedicine products.

Authors:  Michael L Etheridge; Stephen A Campbell; Arthur G Erdman; Christy L Haynes; Susan M Wolf; Jeffrey McCullough
Journal:  Nanomedicine       Date:  2012-06-06       Impact factor: 5.307

4.  MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression.

Authors:  Jing Yan; Jing-yi Jiang; Xiao-Na Meng; Yin-Ling Xiu; Zhi-Hong Zong
Journal:  J Exp Clin Cancer Res       Date:  2016-02-13

Review 5.  Engineering targeted viral vectors for gene therapy.

Authors:  Reinhard Waehler; Stephen J Russell; David T Curiel
Journal:  Nat Rev Genet       Date:  2007-07-03       Impact factor: 53.242
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.